Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CNTO 328 Clear all
Completed Phase 1 Interventional

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

NCT00412321
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node Hyperplasia
Interventions
CNTO 328
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Little Rock, Arkansas • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Sep 6, 2026, 4:56 PM EDT
Withdrawn Phase 2 Interventional

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

NCT06352866
View directory record Official record
Conditions
Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Siltuximab, Teclistamab(FDA-approved)
Drug
Lead sponsor
Jack Khouri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 6, 2026, 4:56 PM EDT
Not listed Phase 1Phase 2 Interventional

Siltuximab in Schizophrenia

NCT02796859
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Siltuximab, normal saline
Drug
Lead sponsor
Brian Miller
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

NCT01219010
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Siltuximab
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Chicago, Illinois • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

NCT04975555
View directory record Official record
Conditions
Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
Interventions
Siltuximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

NCT05665725
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Siltuximab
Procedure · Biological
Lead sponsor
Timothy Voorhees
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 6, 2026, 4:56 PM EDT
Recruiting Phase 2 Interventional

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

NCT06679829
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Melphalan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Early Phase 1 Interventional Results available

Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

NCT02641522
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Siltuximab
Drug
Lead sponsor
Carla Greenbaum, MD
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

NCT01484275
View directory record Official record
Conditions
High-risk Smoldering Multiple Myeloma
Interventions
Siltuximab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
8
States / cities
Chicago, Illinois • Rockville, Maryland • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00433446
View directory record Official record
Conditions
Prostate Cancer
Interventions
CNTO 328
Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
123
States / cities
Anniston, Alabama • Springdale, Arkansas • Berkeley, California + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 6, 2026, 4:56 PM EDT
Terminated Early Phase 1 Interventional

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

NCT05316116
View directory record Official record
Conditions
Large Granular Lymphocyte Leukemia
Interventions
Siltuximab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Recruiting Phase 2 Interventional

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

NCT06470971
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions
Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Siltuximab
Biological · Procedure · Other
Lead sponsor
Yuanquan Yang
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation

NCT06990711
View directory record Official record
Conditions
Antibody Mediated Rejection of Lung Transplant
Interventions
Siltuximab, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Saint Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional

SILtuximab in Viral ARds (SILVAR) Study

NCT04616586
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Lung Diseases, Pneumonia, Respiratory Tract Infections, Respiratory Tract Disease
Interventions
Siltuximab, Normal Saline
Drug · Other
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
12 Years to 65 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Lansing, Michigan • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 6, 2026, 4:56 PM EDT
Recruiting Phase 1 Interventional

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

NCT06447376
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Cytokine Release Syndrome
Interventions
Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin
Drug
Lead sponsor
Taylor Brooks
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

NCT00402181
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Dexamethasone
Biological · Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Duarte, California • Norwalk, Connecticut • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 6, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional Results available

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

NCT01513317
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Siltuximab, Placebo, Best supportive care (BSC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

NCT00401843
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Bortezomib, Placebo, Dexamethasone
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
11
States / cities
Greenbrae, California • Los Angeles, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 6, 2026, 4:56 PM EDT
Active, not recruiting Phase 2 Interventional

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

NCT03315026
View directory record Official record
Conditions
Multiple Myeloma, AL Amyloidosis
Interventions
Siltuximab, The M.D. Anderson Symptom Inventory (MDASI)
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants

NCT02074800
View directory record Official record
Conditions
Healthy
Interventions
CNTO 328 (Sp2/0-derived), CNTO 328 (CHO-derived), Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Lincoln, Nebraska • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

NCT00911859
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab11 mg/kg, Siltuximab 8.3 mg/kg or 11 mg/kg, Velcade (bortezomib), Melphalan, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00401765
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CNTO 328, Docetaxel
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Sep 6, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional

Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

NCT04838860
View directory record Official record
Conditions
Idiopathic Multicentric Castleman's Disease
Interventions
Siltuximab
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

NCT01400503
View directory record Official record
Conditions
Multicentric Castleman's Disease
Interventions
Siltuximab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
7
States / cities
Little Rock, Arkansas • Tampa, Florida • Lansing, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 6, 2026, 4:56 PM EDT